Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066648 · ClinicalTrials.gov registry record · Phase 1
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 241
- Enrollment target
NCT03066648 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 241 participants.
The verdict
NCT03066648, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 241 participants
- Enrollment target
Study Summary
To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG PDR001
- DRUG MBG453
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2017-07-06 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03066648
The ClinicalTrials.gov registry entry for NCT03066648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Azacitidine is the first listed.
NCT03066648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03066648 about?
NCT03066648 is a clinical study titled "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS". To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine or azacitidine in AML and intermediate or high- risk MDS patients, and to identify recommended doses for future studies.
What is the current status of trial NCT03066648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 241 participants. The study started on 2017-07-06. Estimated completion is 2023-09-08.
What interventions are being tested in trial NCT03066648?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), PDR001 (DRUG), MBG453 (DRUG).
Who is sponsoring clinical trial NCT03066648?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.